Currently, targeted therapy agents Crizotinib and Copanlisib approved for the treatment of tumours that harbour mutations in ROS1/MET/ALK and PIK3CA, while therapeutic agents for the other identified variants, including FGFR family, MYC, MET, and KRAS are currently under investigation in active and ongoing clinical trials. Here, MYC is linked to neoplasm.